The Directors of CBD Science Group PLC recognize the importance of the highest standards as it relates to corporate governance.
Details go here.
There are three committees of the Board, details of which can be found by clicking on the links below:
There are three committees of the Board, details of which can be found by clicking on the links below:
The Board attaches great importance to effective communication with shareholders and encourages dialogue with both its institutional and private investors and responds promptly to all questions received verbally or in writing. Regular communication is maintained with all shareholders through Company announcements, the Annual Report and Accounts, Preliminary Results and the Interim Report. Directors regularly attend meetings with analysts and institutional shareholders throughout the year. With private shareholders this is not always practical. The Board has therefore sought to use the Company’s Annual General Meeting as the opportunity to meet private shareholders, after which the Board gives a presentation on the activities of the Group and there is also an opportunity to ask questions of Directors on a formal and informal basis. All shareholders have at least 21 days’ notice of the Annual General Meeting.
In addition the Company operates this website as an important investor communications tool. This website contains further details of the Group and its activities, details of regulatory announcements and Company announcements, Annual and Interim Reports, and details of the Company’s share price, share trading activity and graphs.
There is an organisational structure with clearly defined lines of responsibility and delegation of accountability and authority.
The Directors have overall responsibility for ensuring that the Group maintains a system of internal control to provide them with reasonable assurance that the assets of the Group are safeguarded and that the shareholders’ investments are protected. The system includes internal controls covering financial, operational and compliance areas, and risk management. There are limitations in any system of internal control, which can provide reasonable but not absolute assurance with respect to the preparation of financial information, the safeguarding of assets and the possibility of material misstatement or loss.
The Board has considered and reviewed the system of internal controls in place in accordance with the Turnbull Report. An assessment of the major risk areas for the business and methods used to monitor and control them was also undertaken. In addition to financial risk, the review covered operational, commercial, environmental, regulatory and research and development risks. The risk review is an ongoing process with regular review by the Board at least annually.
The key procedures designed to provide an effective system of internal control that have operated throughout the year and up to the date of the sign-off of this report are described below.
GW Pharmaceuticals plc is incorporated in England (Registration number 4160917) which is also its main country of operation. GW Pharma is subject to the UK City Code on Takeovers and Mergers.
There is an organisational structure with clearly defined lines of responsibility and delegation of accountability and authority.
